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and Guangheng Li1*Abstract
Background: The major disadvantage of using a stem cell-based bone morphogenetic protein-4 (BMP4) gene therapy
for skull defect is the overgrowth of generated bone tissue in situ. In the present study, to overcome bony overgrowth of
stem cell based-gene therapy, a new strategy of two-stage bone tissue engineering by an adeno-associated virus
containing BMP4 gene (AAV-BMP4) gene therapy was used.
Methods: AAV-BMP4 was purposely implanted in the skeletal muscle of mice to generate ectopic bone tissues
during the first stage. Next, the newly formed ectopic bone tissues were harvested and then transplanted to
repair the mouse skull defect during the second stage.
Results: The results showed that skeletal muscle implantation of AAV-BMP4 yielded a large amount of new bone
tissues. The ectopic bone tissues can be harvested as a bone graft and can successfully repair the mouse skull defect
without any bony overgrowth in situ.
Conclusion: The results indicate that the bone tissues purposely generated by AAV-BMP4 in the skeletal muscle may
be a new alternative of bone grafting for clinical purposes.
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Patients with clinical situations, such as skull defect,
chronic non-unions of fracture, or spinal fusion may re-
quire repeated autologous bone grafts. The disadvantages
of using autologous bone grafts include limited availability,
donor-site morbidity, and reduced osteogenicity. Wright
et al. have repaired long-bone and cranial defects by utiliz-
ing muscle-derived stem cells (MDSCs) transfected with
bone morphogenetic proteins (BMPs) [1–3]. However, this
approach has its limitation because MDSCs normally gen-
erate inappropriate overgrowth of bone tissue in situ. Al-
though Hannallah et al. reported that the inappropriate* Correspondence: liguangheng@hotmail.com
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© 2015 Tian et al.overgrowth can be prevented by multiple gene therapies,
such as the combination of BMP4 and Noggin (BMP4 an-
tagonist), the transfected cells must be tightly regulated
which make the procedure difficult to manage [4, 5]. Be-
sides, the stem cell-based gene therapy is lengthy consider-
ing the time required for stem cell isolation, in vitro
transfection, and implantation of cells until ossification in
the defect is observed [6–8].
It is known that ectopic bone tissues in the skeletal
muscle can be induced by injecting adeno-associated vi-
ruses (AAV) containing the bone morphogenetic protein
(BMP) gene [9, 10]. However, it remains uncertain whether
the bone tissue generated by the AAV-BMP4 induction can
be used as a bone graft. Therefore, in the present study, a
new strategy was used to overcome the disadvantages of
stem cell-based gene therapy for the skull defect repair. In
this strategy, ectopic bone formation in the skeletal was
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the first stage, and then the bone tissues were harvested
and tested for its grafting capacity for skull defect repair
during the second stage. Results generated from the present
study provide us with a better understanding about ectopi-
cally formed bone tissues triggered by AAV-BMP4 in the
skeletal muscle, which may be a new strategy for treating
clinical patients with a need for bone grafts.Methods
Construction and production of AAV-BMP4
Human BMP4 gene was carried by self-complementary
AAV vectors [11]. The viral vector stocks of serotypes 6 of
AAV-D(+)-BMP-4 were produced and purified according
to published protocols [11], and vector titers were approxi-
mately 5 × 1012 viral particles per ml (vp/ml).Fig. 1 Two-stage therapeutic utility of ectopically formed bone tissue induce
therapeutic utility of ectopically formed bone tissue induced by AAV-BMP4 in
process of endochondral bone formation was triggered by the AAV-BMP4 wit
(d) tissues were observed at weeks 2 and 4 after the implantation, respectivel
2 (e), 12 (f), and 24 (g) after implantation. The density of ectopic bone tissuesSkeletal muscle implantation of AAV-BMP4 in SCID mice
The animal protocol using severe combined immune-
deficient (SCID) mice in the present study was approved by
the Experimental Animal Review Board of Zhengzhou
University. Twelve pieces of Gelfoam (Pfizer, Kalamazoo,
Michigan, 3 × 3 mm2) soaked with 15 μl AAV-BMP4
(5 × 1012 vp/ml) were implanted into both legs of six
SCID mice. These mice were assessed by micro-CT at
weeks 2, 12, and 24 after implantation surgery (Fig. 1a).
Harvesting and transplantation of bone tissues in vivo
The mice with AAV-BMP4 implantation surgery were
sacrificed and ectopically generated bone tissue in the
skeletal muscle pocket was harvested at week 12. At
the same time, another set of twelve host mice with
skull defects were surgically created [5]. Six of the 12
mice are the recipients of these freshly harvested boned by AAV-BMP4 in skeletal muscle. a Experimental design of two-stage
skeletal muscle. b–d H&E staining of sample sections showing that the
h Gelfoam implantation in the muscle pocket. Cartilage (c) and bone
y. e–g μCT assessments showed ectopic bone tissues appeared at weeks
increased with time
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the other 6 mice have no treatment and were used as
the control group. Harvested bone tissue was shaped
and resized to fit a 6-mm-diameter skull defect and
then transplanted into six host mice (Fig. 1a). The inci-
sion was sutured closed, and mice were housed as
normal.
Micro-CT exams
After AAV-BMP4 implantation, mice were checked by
micro-computed tomography (μCT) at weeks 2, 12, and 24
after surgery. The mice with skull defects were also checked
by μCT at weeks 4, 12, and 24 after bone graft transplant-
ation surgery.
Von Kossa/eosin staining
Frozen sections were fixed in 10 % formalin for 10 min and
were rinsed in distilled water three times. The slides were
stained in 2 % silver nitrate solution in the dark for 15 min,
rinsed three times in distilled water, and exposed to light
for 15–30 min until appropriate stain development. These
sections were counterstained with eosin according to the
protocol [12].
Results
Bone tissues were generated in the hind limb skeletal
muscle pocket with AAV-BMP4 Gelfoam implantation
in vivo
Implantation of Gelfoam containing 15 μl of AAV-BMP4
(5 × 1012 vp/ml) in the muscle pocket induced a large
amount of ectopic bone tissue histologically (Fig. 1d) and
was confirmed by μCT at 2 weeks post implantation
(Fig. 1e).
Ectopic bone formation by implantation of AAV-BMP4
Gelfoam underwent endochondral process
Implantation of AAV-BMP4 with Gelfoam yielded a large
amount of bone tissue in the skeletal muscle by both histo-
logically and μCT measurement. The process of bone for-
mation is through endochondral bone formation. Normal
histological structure of skeletal muscle is observed prior to
AAV-BMP4 with Gelfoam implantation (Fig. 1b). Notice-
able cartilage tissue is observed in the tissue section at week
2 after AAV-BMP4 with Gelfoam implantation (Fig. 1c),
and bone tissue has formed by week 4 (Fig. 1d). μCTassess-
ment demonstrated ectopic bone tissue formation at weeks
2, 12, and 24 after implantation. The bone density increased
with time (Fig. 1e–g).
Transplanted bone graft successfully repaired the skull
defect of the host mouse
The transplanted bone tissues successfully repaired the
skull defect by μCT examinations at various time pointsafter surgery. The bone graft gradually modified its di-
mension with time (Fig. 2a). There is no overgrowth of
transplanted bone tissues at the site of the skull defect
(Fig. 2b). Under μ-CT and histological examinations, the
bony edge of the graft fused with the host bony skull de-
fect effectively in time (Fig. 2c, d).Discussions
Skeletal muscle is reported as the easiest infected organ
for AAV when compared to other organs in several
in vivo studies [11, 13]. In the present study AAV-BMP4
works very effectively to transform a large amount of skel-
etal muscles into similar amount of bone tissues in vivo.
The histological observations also proved that the process
underwent the endochondral bone formation.
Ideally, the new bone regeneration strategy should be
simple, cost effective, and as minimally invasive as pos-
sible to lessen donor-site morbidity [13–15]. In the
present study, the thought of two-stage bone grafting
was tested (Fig. 2a). The results demonstrated that ec-
topic bone tissue has good efficiency and practicality for
bone grafting. As thought, the method was superior for
the following reasons when compared to the traditional
stem cell-based gene therapy. This method omitted a
huge amount of in vitro work which included the isola-
tion of stem cells, culturing, passage, virus transduction,
and final implantation [16–18]. The bone tissues gener-
ated in the muscle pocket are easily harvested and ap-
plied in the skull defect. Our results also demonstrated
that harvested bone tissues repaired the skull defect
without the overgrowth of bone tissues, which is a major
side complication of conventional stem cell-based BMP4
gene therapy [5].
The concept of the present study was to help clinicians
deal with patients with fracture non-union, bone defects,
and spinal fusion. This method will enable one or several
“unnecessary” pieces of skeletal muscle of patients to be
transformed into the bone tissues needed for bone graft-
ing in vivo. By saying the “unnecessary”, it means that
transforming the piece of skeletal muscle into bone tis-
sue does not affect normal body function severely. The
transformed pieces of skeletal muscles could be the least
used muscles or some muscles which did not affect the
normal human body function after being removed, such
as human palmaris longus muscle and plantaris muscle.
As we know, there are around 650 skeletal muscles in
the human body and they make up around half of the
total human body weight. Skeletal muscle might become
a potential bony autograft bank for patients with a need
for bone grafting if the concept of the present study suc-
ceeds in future human clinical trial. Future work will in-
vestigate how to control the size and orientation of
ectopic bone tissue in vivo in its first stage, as well as its
Fig. 2 Ectopic bone tissues repaired skull defect successfully. a μCT assessment showed harvested ectopic bone tissues repaired skull bone defect
effectively with time. NC stands for negative control which has no graft implantation. b At week 24 after transplantation, μCT assessments showed there
was no bony overgrowth of transplanted ectopic bone graft for skull defect when compared to the MDSC-based gene therapy (bi). c Transplanted bone
graft fused well with the host bone edge of skull defect with time. d Histological results demonstrated that harvested bone graft fused with the host bone
tissue efficiently at week 24 post transplantation by von Kossa/eosin staining of sample section
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of skull defect.
Conclusion
Ectopically formed bone tissues triggered by AAV-BMP4
in the skeletal muscle can be used as bone graft for
repairing the skull defect, which may be a new strategy
for treating clinical orthopedic patients with a need for
bone grafts.
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